568 related articles for article (PubMed ID: 17717634)
1. The other side of MMPs: protective roles in tumor progression.
Martin MD; Matrisian LM
Cancer Metastasis Rev; 2007 Dec; 26(3-4):717-24. PubMed ID: 17717634
[TBL] [Abstract][Full Text] [Related]
2. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment.
Zucker S; Cao J; Chen WT
Oncogene; 2000 Dec; 19(56):6642-50. PubMed ID: 11426650
[TBL] [Abstract][Full Text] [Related]
3. Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies.
Folgueras AR; Pendás AM; Sánchez LM; López-Otín C
Int J Dev Biol; 2004; 48(5-6):411-24. PubMed ID: 15349816
[TBL] [Abstract][Full Text] [Related]
4. [Matrix metalloproteinases and colorectal cancer].
Roeb E; Matern S
Med Klin (Munich); 2003 Dec; 98(12):763-70. PubMed ID: 14685678
[TBL] [Abstract][Full Text] [Related]
5. [Extracellular matrix -- from basic research to clinical significance. An overview with special consideration of matrix metalloproteinases].
Hamacher S; Matern S; Roeb E
Dtsch Med Wochenschr; 2004 Sep; 129(38):1976-80. PubMed ID: 15375740
[TBL] [Abstract][Full Text] [Related]
6. Matrix metalloproteinases and bladder cancer.
Kanayama H
J Med Invest; 2001 Feb; 48(1-2):31-43. PubMed ID: 11286015
[TBL] [Abstract][Full Text] [Related]
7. Matrix metalloproteinases in tumour invasion and metastasis.
Curran S; Murray GI
J Pathol; 1999 Nov; 189(3):300-8. PubMed ID: 10547590
[TBL] [Abstract][Full Text] [Related]
8. Anti-invasive, antitumoral, and antiangiogenic efficacy of a pyrimidine-2,4,6-trione derivative, an orally active and selective matrix metalloproteinases inhibitor.
Maquoi E; Sounni NE; Devy L; Olivier F; Frankenne F; Krell HW; Grams F; Foidart JM; Noël A
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4038-47. PubMed ID: 15217936
[TBL] [Abstract][Full Text] [Related]
9. Matrix metalloproteinase-2 involvement in breast cancer progression: a mini-review.
Jezierska A; Motyl T
Med Sci Monit; 2009 Feb; 15(2):RA32-40. PubMed ID: 19182722
[TBL] [Abstract][Full Text] [Related]
10. Matrix metalloproteinase 11 (MMP-11; stromelysin-3) and synthetic inhibitors.
Matziari M; Dive V; Yiotakis A
Med Res Rev; 2007 Jul; 27(4):528-52. PubMed ID: 16710861
[TBL] [Abstract][Full Text] [Related]
11. Modifying the soil to affect the seed: role of stromal-derived matrix metalloproteinases in cancer progression.
Jodele S; Blavier L; Yoon JM; DeClerck YA
Cancer Metastasis Rev; 2006 Mar; 25(1):35-43. PubMed ID: 16680570
[TBL] [Abstract][Full Text] [Related]
12. The role of matrix metalloproteinases in tumor invasion, metastasis, and angiogenesis.
Stetler-Stevenson WG
Surg Oncol Clin N Am; 2001 Apr; 10(2):383-92, x. PubMed ID: 11382593
[TBL] [Abstract][Full Text] [Related]
13. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting.
Gialeli C; Theocharis AD; Karamanos NK
FEBS J; 2011 Jan; 278(1):16-27. PubMed ID: 21087457
[TBL] [Abstract][Full Text] [Related]
14. The role of the IGF-I receptor in the regulation of matrix metalloproteinases, tumor invasion and metastasis.
Zhang D; Samani AA; Brodt P
Horm Metab Res; 2003; 35(11-12):802-8. PubMed ID: 14710361
[TBL] [Abstract][Full Text] [Related]
15. Matrix metalloproteinases in colorectal cancer.
Mysliwiec AG; Ornstein DL
Clin Colorectal Cancer; 2002 Feb; 1(4):208-19. PubMed ID: 12450419
[TBL] [Abstract][Full Text] [Related]
16. The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia.
Klein G; Vellenga E; Fraaije MW; Kamps WA; de Bont ES
Crit Rev Oncol Hematol; 2004 May; 50(2):87-100. PubMed ID: 15157658
[TBL] [Abstract][Full Text] [Related]
17. [Metalloproteinases in tumor progression. Review].
Arvelo F; Cotte C
Invest Clin; 2006 Jun; 47(2):185-205. PubMed ID: 16886780
[TBL] [Abstract][Full Text] [Related]
18. Three matrix metalloproteinases are required in vivo for macrophage migration during embryonic development.
Tomlinson ML; Garcia-Morales C; Abu-Elmagd M; Wheeler GN
Mech Dev; 2008; 125(11-12):1059-70. PubMed ID: 18684398
[TBL] [Abstract][Full Text] [Related]
19. Matrix metalloproteinases in tumor-host cell communication.
Lynch CC; Matrisian LM
Differentiation; 2002 Dec; 70(9-10):561-73. PubMed ID: 12492497
[TBL] [Abstract][Full Text] [Related]
20. Repression of matrix metalloproteinase gene expression by ginsenoside Rh2 in human astroglioma cells.
Kim SY; Kim DH; Han SJ; Hyun JW; Kim HS
Biochem Pharmacol; 2007 Dec; 74(11):1642-51. PubMed ID: 17880928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
